New York, New York--(Newsfile Corp. - July 24, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against EquipmentShare.Com Inc ("EquipmentShare" or the "Company") (NASDAQ: EQPT) on behalf of investors who purchased or otherwise acquired EquipmentShare common stock pursuant and/or traceable to the Company's initial public offering on or around January 23, 2026 (the "IPO"), or between January 23, 2026 and June 23, 2026 (the "Class Period").
CLICK HERE TO JOIN THE CASE
If you are an investor in EquipmentShare and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.
DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than September 21, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.
According to the complaint, in the IPO, the Company sold 30.5 million shares of Class A common stock at a price of $24.50 per share. Then, on June 24, 2026, according to the complaint, "Umibōzu Research, a stock market focused media outlet, published a report alleging, among other things, that 'undisclosed related party transactions . . . have netted' entities affiliated with EquipmentShare founders 'at least $77 million, with the true figure potentially running substantially higher.'" According to the complaint, on this news EquipmentShare's stock price fell $1.58, or 6.62%, to close at $22.30 on June 24, 2026, and declined $2.61, or 11.7%, the next trading day to close at $19.69 per share on June 25, 2026.
WHY CONTACT KAPLAN FOX?
Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.
Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.
For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.
If you have any questions about this Notice, your rights, or your interests, please contact:
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
New York, New York--(Newsfile Corp. - July 24, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Verra Mobility Corporation ("Verra Mobility" or the "Company") (NASDAQ: VRRM) on behalf of investors that purchased or otherwise acquired Verra Mobility common stock between February 24, 2026 and May 26, 2026 (the "Class Period").
CLICK HERE TO JOIN THE CASE
If you are an investor in Verra Mobility and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.
DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than August 4, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.
On May 26, 2026, Verra Mobility issued a press release disclosing that the Company had received a termination notice from Avis Budget Group regarding its contract, which becomes effective in September 2026. Verra Mobility further disclosed that it "expects the termination to reduce Commercial Services' 2026 annualized revenue by approximately $135 million to $145 million and 2026 annualized segment profit by approximately $120 million to $125 million, before taking into account expected cost reduction initiatives." Verra also lowered its full year 2026 financial outlook.
Following this news, Verra Mobility's stock price fell $9.23 per share, or 70.6%, to close at $3.85 per share on May 27, 2026.
The complaint alleges that throughout the Class Period, Defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Verra Mobility's relationship with Avis Budget Group.
WHY CONTACT KAPLAN FOX?
Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.
Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.
For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.
If you have any questions about this Notice, your rights, or your interests, please contact:
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Verra Mobility Corporation (NASDAQ: VRRM).
Key Takeaways Axon Enterprise is growing across devices and software but faces higher costs, debt and a richer valuation.Woodward expects strong fiscal 2026 sales growth, backed by aerospace demand and industrial strength.WWD combines lower valuation, shareholder returns and growth prospects, making it the stronger pick. Axon Enterprise, Inc. (AXON - Free Report) and Woodward, Inc. (WWD - Free Report) are two familiar names operating in the aerospace and defense equipment industry. As rivals, these companies are engaged in producing highly engineered public security and defense solutions in the United States and internationally.
Both companies have been enjoying significant growth opportunities in the public safety and defense industries on account of growing instances of terrorism and criminal activities and the expansionary U.S. budgetary policy. Let’s take a closer look at their fundamentals, growth prospects and challenges.
The Case for AxonAxon’s Connected Devices segment is thriving on the back of strong demand for TASER devices. Solid demand for virtual reality training services, TASER 10 handle and counter-drone equipment also supports the segment’s growth. Segmental revenues surged 33% year over year in the first quarter of 2026, following an increase of 29.1% in 2025.
The company continues to witness growing popularity for its next-generation TASER 10 products, whose shipment began in 2023. Growth in cartridge revenues, driven by higher adoption of the TASER products, has been driving the segment’s performance.
An increase in the aggregate number of users to the Axon network is aiding the Software & Services segment. After witnessing a year-over-year 39.6% jump in revenues in 2025, revenues from the segment increased 35% in first-quarter 2026. Continued momentum in digital evidence management and increased adoption of its latest software offerings are driving the segment’s growth.
The company is strengthening its foothold in the counter-drone space with the growing capabilities of its Dedrone offerings and Artificial Intelligence (AI)-powered command-and-control platform. It recently launched Dedrone C2, an upgraded version of the Dedrone platform. This C2 version comes with enhanced sensor fusion technology, offering stronger detection capabilities.
AXON has also been focusing on strategic collaborations with other companies to expand its counter-drone capabilities and customer base. Last year, Axon entered into a partnership with TYTAN (a leading provider of interceptor systems for Group 3 drones) to boost detection, identification and mitigation capabilities of counter-drone equipment.
On the flip side, escalating costs and expenses are a concern for Axon’s bottom line. In the first three months of 2026, its cost of sales and SG&A expenses increased 38.8% and 15.9%, respectively, year over year. Total operating expenses climbed 19.6% year over year to $448 million. The company incurred high costs and expenses related to business integration activities and stock-based compensation expenses.
Axon has been facing the pressure of rising debt levels. Exiting the first quarter of 2026, the company’s long-term notes payable (net) were $1.73 billion. This increase was primarily due to funds raised to support the company’s strategic investments, expansion activities and potential acquisitions. Considering its high debt level, its cash and cash equivalents of $458.9 billion do not look impressive.
The Case for WoodwardWoodward’s Aerospace business is gaining momentum with strength in the commercial aftermarket as well as higher defense activity, despite supply-chain challenges. In the second quarter of fiscal 2026 (ended March 2026), net sales for the segment were up 25% year over year, driven by broad-based strength across commercial services and defense OEM. Driven by strength across its business, Woodward projects its Aerospace segment to grow 21–24% in fiscal 2026 (ending September 2026), up from the earlier estimated 15–20% range.
The company’s Industrial business segment continues to benefit from solid demand for power generation equipment and services, along with favorable conditions in marine transportation and steady investment in parts of oil and gas. In the fiscal second quarter, Industrial sales increased 20% year over year, with Core Industrial sales up 19% excluding China on-highway. For fiscal 2026, Woodward expects consolidated net sales to rise 20-23%, with the Industrial segment anticipated to increase 18-20%.
The company’s disciplined capital deployment remains focused on organic growth, returning cash to shareholders and pursuing strategic acquisitions. As part of this strategy, the company is making a multiyear investment in a new state-of-the-art facility to support the Airbus A350 spoiler actuation program and long-term organic growth. Also, it closed the acquisition of Valve Research & Manufacturing in March 2026. The buyout will complement Woodward’s engineering, design and manufacturing capabilities in fuel and motion control systems.
During the first six months of fiscal 2026, the company returned $391.1 million to its shareholders in the form of $35.8 million of dividends and $355.3 million of share repurchases. Also, in November 2025, WWD’s board approved a new $1.8 billion share repurchase authorization over three years, underscoring confidence in the company’s strong balance sheet and long-term growth outlook.
Its healthy liquidity position adds to its strength. Management continues to guide $300-$350 million of free cash flow for fiscal 2026 and about $290 million of capital expenditures, and highlighted inventory initiatives are intended to improve cash generation in fiscal 2027.
Price Performance
Image Source: Zacks Investment Research
In the past six months, Axon shares have lost 18.7%, while Woodward stock has gained 24.4%.
The Zacks Consensus Estimate for AXON & WWDThe Zacks Consensus Estimate for AXON’s 2026 sales and earnings per share (EPS) implies year-over-year growth of 31.5% and 14.3%, respectively. The EPS estimates for both 2026 and 2027 have been stable over the past 60 days.
Image Source: Zacks Investment Research
The consensus estimate for WWD’s fiscal 2026 sales implies growth of 21.2% year over year, while the EPS estimate implies a 35.6% increase. WWD’s EPS estimates for fiscal 2026 and 2027 (ending September 2027) have remained unchanged over the past 60 days.
Image Source: Zacks Investment Research
Woodward’s Valuation Attractive Than AxonWoodward is trading at a forward 12-month price-to-earnings ratio of 40.15X, while Axon’s forward earnings multiple sits much higher at 52.27X.
Image Source: Zacks Investment Research
ConclusionAxon’s strong momentum across operational segments and growing presence in the counter-drone space have been dented by rising expenses and a high debt level, which might affect its margins and performance. Also, AXON’s expensive valuation warrants a cautious approach for existing investors.
In contrast, Woodward’s market leadership position and strength in aerospace and industrial businesses provide it with a competitive advantage to leverage the long-term demand prospects in the market. WWD holds robust prospects due to strong estimates, stock price appreciation, attractive valuation and solid prospects for sales and profit growth.
Given these factors, WWD seems to be a better pick for investors than AXON currently. While WWD currently carries a Zacks Rank #2 (Buy), AXON has a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Key Takeaways SIGI beat Q2 earnings as stronger underwriting and investment income offset lower premiums written. SIGI improved its combined ratio to 98% and raised its 2026 after-tax net investment income outlook. SIGI repurchased shares and posted its eighth straight quarter of double-digit operating returns. Selective Insurance Group, Inc. (SIGI - Free Report) reported second-quarter 2026 operating earnings of $1.95 per share, which beat the Zacks Consensus Estimate by 13.4%. The bottom line increased 48.9% year over year.
Revenues of $1.37 billion rose 4.5% from the year-ago quarter and topped the consensus estimate by 0.7%. Results benefited from stronger investment income and improved underwriting, while lower premiums written reflected continued portfolio actions.
SIGI's Underwriting Results ImproveNet premiums written declined 5% year over year to $1.22 billion due to a 6% decrease in Standard Commercial Lines, an 8% fall in Standard Personal Lines, and a 2% decline in Excess and Surplus Lines. Our estimate was $1.33 billion.
Net premiums earned increased 2.3%. Direct new business fell to $206.1 million from $248.1 million. Renewal pure price increases averaged 6.5%, down from 9.9% in the prior-year quarter.
The combined ratio improved 220 basis points to 98%. Lower catastrophe and non-catastrophe property losses, along with no prior-year casualty reserve development, supported the improvement. Higher current-year casualty loss costs partly offset these benefits.
SIGI's Investment Income Adds SupportAfter-tax net investment income increased 18% year over year to $119.2 million. Net investment income per common share rose 20% to $1.98.
The after-tax yield was 4.4% for fixed-income securities and 4.2% for the overall portfolio. Investment income contributed 13.9 percentage points to annualized return on equity, up from 13 points a year ago.
SIGI's Commercial Lines Performance StrengthensStandard Commercial Lines net premiums written fell 6% year over year to $961.9 million as lower new business weighed on production. Our estimate was $1 billion.
Net premiums earned rose 3% to $962 million, while retention was 81%.
The segment's combined ratio improved 350 basis points to 99.3%. The improvement reflected no prior-year casualty reserve development and lower non-catastrophe property losses, partly offset by higher current-year casualty loss costs.
SIGI's Personal Lines Margin NarrowsStandard Personal Lines net premiums written declined 8% to $101.5 million, while net premiums earned decreased 5% to $97.6 million. Our estimate for net premiums written was $111.4 million. New business fell 36%, renewal pure price increased 8.9% and retention remained at 79%.
The segment's combined ratio deteriorated 390 basis points to 95.5%. Higher non-catastrophe property losses and a higher expense ratio pressured the result, though lower catastrophe losses provided some relief.
SIGI's Excess and Surplus Results Stay ProfitableExcess and Surplus Lines net premiums written decreased 2% year over year to $157.3 million. Our estimate was $174.7 million. Net premiums earned increased 5% to $155.8 million, while average renewal pure price rose 3.4%.
The segment's combined ratio increased 200 basis points to 91.8%. Higher current-year casualty loss costs and non-catastrophe property losses more than offset lower catastrophe losses.
SIGI's Profitability and Capital ImproveAfter-tax underwriting income was $19.3 million against a loss of $1.9 million a year earlier. Non-GAAP operating income climbed 46% to $117.6 million, while net income available to common stockholders increased 52% to $127.1 million.
Operating return on common equity improved 340 basis points year over year to 13.7%. The company marked its eighth consecutive quarter of double-digit operating returns.
Total expenses increased slightly to $1.22 billion from $1.21 billion, reflecting higher other insurance expenses. Our estimate was $1.24 billion.
SIGI's Balance Sheet Gains GroundSelective Insurance ended the quarter with total assets of $15.62 billion, up 3% from year-end 2025. Total investments increased 2% to $11.58 billion, while common stockholders' equity rose 2% to $3.46 billion.
Book value per common share was $58.13, up 3% sequentially, while adjusted book value per share increased 3% to $60.56. During the quarter, the company repurchased $32 million of shares at an average price of $84.72.
Selective Insurance Raises Investment Income OutlookFor 2026, Selective Insurance continues to expect a GAAP combined ratio of 96.5-97.5, including 6 points of catastrophe losses. The outlook assumes no prior-year casualty reserve development.
The company raised its after-tax net investment income guidance to $480 million from $465 million. It continues to project an effective tax rate of 21.5% and now expects weighted average diluted shares of 60.2 million.
Zacks RankSelective Insurance currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Performance of Other Property and Casualty InsurersChubb Limited (CB - Free Report) reported second-quarter 2026 core operating earnings of $7.26 per share, which beat the Zacks Consensus Estimate of $6.63 by 9.5%. The bottom line increased 18.2% year over year. Revenues rose 2.7% year over year to $15.77 billion but missed the consensus mark of $15.90 billion by 0.8%.
Stronger P&C underwriting, record investment income, and higher life insurance income supported results. Net premiums earned increased 5.8% to $13.89 billion. P&C underwriting income increased 18.8% year over year to $1.94 billion. The combined ratio improved 180 basis points to 83.8%, reflecting a lower share of premiums consumed by claims and expenses. Our estimate was $1.15 billion.
The Travelers Companies, Inc. (TRV - Free Report) reported second-quarter 2026 core income of $10.04 per share, which beat the Zacks Consensus Estimate of $5.21 by 92.7%. The bottom line climbed 54% year over year. Revenues of $12.09 billion missed the Zacks Consensus Estimate of $12.27 billion by 1.5%.
Net investment income rose 14% year over year to $1.07 billion pre-tax ($883 million after tax). The combined ratio improved 670 basis points year over year to 83.6%, reflecting lower catastrophe losses, stronger reserve development and a better underlying combined ratio.
W.R. Berkley Corporation (WRB - Free Report) reported second-quarter 2026 operating income of $1.27 per share, which beat the Zacks Consensus Estimate by 16.5%. The bottom line increased 21% year over year. W.R. Berkley’s net premiums written were about $3.4 billion, up 2.4% year over year. The figure surpassed our estimate of $3.4 billion.
Operating revenues totaled $ 3.8 billion, up 3.6% year over year. The top line surpassed the consensus estimate by 1.87%. Net investment income grew 10.4% to $418.7 million, supported by higher invested assets and higher portfolio yields. The figure topped our estimate of $407 million. The consensus estimate was $395.6 million.
Key Takeaways Baxter is set to report Q2 results with revenues and EPS expected to decline year over year.BAX faces pressure from manufacturing inefficiencies, inflation, and Novum pump shipment hold.BAX sees mixed segment trends, with Advanced Surgery strength offset by infusion and pharma weakness. Baxter International Inc. (BAX - Free Report) is scheduled to release second-quarter 2026 results on July 30, before the opening bell. In the last reported quarter, the company’s earnings missed the Zacks Consensus Estimate by 16.13%. BAX’s earnings beat estimates in two of the trailing four quarters and missed twice, delivering an average surprise of 3.12%.
BAX’s Q2 EstimatesThe consensus estimate for revenues is pegged at $2.84 billion, indicating a decline of 0.6% from the prior-year quarter’s reported figure. The consensus mark for earnings is pinned at 36 cents per share, implying a 39% year-over-year decline.
Our model estimates total revenues from continuing operations to decline 2.5% at constant currency (cc) to $2.79 billion. Adjusted earnings per share are expected to decline 39% to 36 cents.
Important Factors to Note Ahead of BAX’s Q2 ResultsBaxter is expected to have delivered a modestly improved second quarter, though results are likely to be constrained by ongoing manufacturing inefficiencies, inflationary cost pressures and the continued shipment hold on its Novum large-volume infusion pump (LVP). Management reiterated its full-year outlook following first-quarter results, indicating that second-quarter earnings may remain on par with the first quarter, with only a slight volume improvement before a more meaningful recovery in the second half.
While end-market demand remains healthy across several businesses, execution-related challenges and difficult year-over-year comparisons are expected to have weighed on profitability.
Within the Medical Products & Therapies (“MPT”) segment, performance is likely to have remained mixed. Advanced Surgery should have continued to outperform, supported by strong global demand for hemostats and sealants along with healthy procedural volumes. However, Infusion Therapies & Technologies is likely to have remained under pressure due to the ongoing Novum LVP shipment and installation hold, lower infusion pump sales and normalization in IV solutions demand following last year's Hurricane Helene-related distributor build.
Management expects pump revenues to improve during the second half as Spectrum adoption increases, but elevated manufacturing absorption costs should have constrained its second-quarter performance. Our model estimates this segment’s revenues to decline 3% at cc to $1.3 billion.
Healthcare Systems & Technologies is expected to post another subdued quarter, with stronger Patient Support Systems demand and a healthy U.S. capital equipment order book partially offset by timing delays in Front Line Care installations. Management continues to expect improvement later in the year as recently launched products, including Connex 360 and the Dynamo smart stretcher, begin contributing more meaningfully. Our model estimates this segment’s revenues to improve 2.9% at cc to $795.1 million.
The Pharmaceuticals segment likely remained challenged by supply constraints within Injectables, softer global demand for inhaled anesthesia products and unfavorable product mix. Nevertheless, improving manufacturing throughput, continued progress clearing back orders and strong growth in drug compounding should have partially mitigated these headwinds. Our model estimates this segment’s revenues to decline 3.6% at cc to $609 million.
Baxter likely continued to face elevated manufacturing costs, tariff-related expenses and inflationary pressures during the second quarter. Management expects these pressures to ease during the second half as higher-cost inventory is worked through, cost-reduction initiatives begin generating savings and operating leverage improves with seasonal volume recovery. Consequently, second-quarter adjusted EPS is likely to have remained near first-quarter levels.
What the Zacks Model Unveils for BAX StockOur proven model does not conclusively predict an earnings beat for Baxter this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
BAX’s Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is -0.99% for Baxter. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank of BAX: Baxter currently has a Zacks Rank #4 (Sell).
BAX’s Share Price PerformanceSo far this year, Baxter’s shares have gained 13.4% against the industry’s 22.5% decline. The S&P 500 has gained 9.3% during the period.
Image Source: Zacks Investment Research
Stocks Worth a LookHere are some stocks from broader medical sector worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle.
Cardinal Health (CAH - Free Report) has an Earnings ESP of +1.24% and a Zacks Rank #2 at present. The company is set to release fourth-quarter fiscal 2026 results on Aug. 11. You can see the complete list of today’s Zacks #1 Rank stocks here.
CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%. The Zacks Consensus Estimate for CAH’s fourth-quarter EPS indicates an improvement of 16.4% from the year-ago reported figure.
Henry Schein (HSIC - Free Report) has an Earnings ESP of +0.41% and a Zacks Rank of 2 at present. The company is scheduled to release second-quarter 2026 results on Aug. 04.
HSIC’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 3.74%. The Zacks Consensus Estimate for HSIC’s second-quarter EPS implies an improvement of 10.9% from the year-ago reported figure.
Agilent Technologies (A - Free Report) has an Earnings ESP of +1.02% and a Zacks Rank of 3 at present.
A’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 1.61%. The Zacks Consensus Estimate for A’s third-quarter fiscal 2026 EPS suggests an improvement of 8% from the year-ago reported figure.
Key Takeaways Cencora is positioned for growth on U.S. healthcare strength, specialty expansion and product launches.COR is integrating OneOncology and RCA to build a scalable specialty care ecosystem across key therapies.Cencora faces pricing headwinds, higher interest expense and regulatory risks despite logistics gains. Cencora (COR - Free Report) is well-poised for growth on the back of a robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern.
This Zacks Rank #2 (Buy) company’s shares have lost 9.7% in the year-to-date period compared with the industry’s 1.8% drop. However, the S&P 500 Index has gained 7.4% in the same time frame.
Cencora is one of the world’s largest pharmaceutical service companies. It is focused on providing drug distribution and related services to reduce healthcare costs and improve patient outcomes. The company has a market capitalization of $58.48 billion.
COR’s bottom line is anticipated to improve 10.1% over the next five years. Its earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 1.6%.
Image Source: Zacks Investment Research
Let’s delve deeper.
Positive Factors Driving COR’s ProspectsSpecialty Expansion and MSO Strategy Support Long-Term Growth: Cencora continues to strengthen its position in specialty pharmaceuticals, a market expected to account for more than half of U.S. drug spending in the coming years. During the second-quarter earnings call, management highlighted progress in integrating OneOncology, acquired in February 2026, with Retina Consultants of America (RCA). Management is leveraging both platforms by sharing capabilities in clinical research, trial support and back-office services, creating a scalable specialty care ecosystem. These investments complement Cencora's broader strategy of deepening manufacturer partnerships while expanding services to community providers, positioning the company to benefit from growing demand for oncology, retina and other specialty therapies.
Pharmaceutical Supply Chain Leadership and Expanding Market Opportunity: Cencora's pharmaceutical-centric strategy remains a competitive advantage. The company continues investing in automated fulfillment centers, digital infrastructure and AI-supported tools that improve inventory management, customer visibility and operational efficiency across the pharmaceutical supply chain. These capabilities reinforce Cencora's role as a critical partner for manufacturers and healthcare providers while supporting long-term customer relationships.
The long-term demand backdrop also remains favorable. Industry forecasts project U.S. pharmaceutical spending to grow at an 8.2% CAGR through 2028, supported by rising prescription volumes, specialty therapies and broader patient access. Cencora is well positioned to benefit from sustained GLP-1 utilization, which contributed nearly $1.9 billion of year-over-year sales growth during the quarter despite moderating growth expectations.
International Business and Specialty Logistics Continue to Improve: Cencora's International Healthcare Solutions segment remained another bright spot. International revenues increased 13% year over year, while operating income rose 13.7%, driven by strong European distribution performance and a second consecutive quarter of operating income growth in global specialty logistics. Management highlighted new contract wins in cell and gene therapies, laboratory logistics and continued momentum at World Courier, reflecting improving execution in complex pharmaceutical logistics.
Key Challenges for COR StockRevenue Mix and Pricing Headwinds Could Pressure Reported Growth: Although prescription demand remains healthy, several factors continue to weigh on reported revenue growth. During the second quarter, manufacturer list price reductions created a roughly $2 billion revenue headwind, while faster-than-expected brand conversions at a large mail-order customer and slower GLP-1 growth prompted management to lower full-year revenue guidance. While these factors have a limited effect on operating income because they primarily involve lower-margin products, they can create volatility in reported sales growth and investor sentiment.
Higher Debt and Ongoing Regulatory Risks Remain Watch Points: The OneOncology acquisition has strengthened Cencora's specialty platform but also increased leverage. Net interest expense rose following the acquisition, and management expects approximately $485 million of interest expense in fiscal 2026 despite continued debt repayment efforts.
Beyond leverage, Cencora operates in a highly regulated pharmaceutical distribution environment. Ongoing opioid-related litigation exposure, controlled-substance monitoring requirements and evolving healthcare reimbursement policies could increase compliance costs or create operational challenges, even as the company continues investing in supply-chain integrity and regulatory compliance.
Estimate TrendCOR has been witnessing a stable estimate revision trend for fiscal 2026. In the past 30 days, the Zacks Consensus Estimate for earnings has remained stable at $17.79 per share.
The consensus mark for third-quarter fiscal 2026 revenues is pegged at $84.89 billion, indicating a 5.2% improvement from the year-ago reported actuals. The bottom-line estimate is pinned at $4.37, implying year-over-year growth of 9.2%.
Other Stocks to ConsiderSome other top-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Cardinal Health (CAH - Free Report) and McKesson (MCK - Free Report) , each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 14.4%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%.
West Pharmaceutical’s shares have gained 29.2% against the industry’s 1.6% decline in the year-to-date period.
Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.
Cardinal Health’s shares have risen 9.9% against the industry’s 1.6% decline in the year-to-date period.
McKesson has a long-term estimated growth rate of 13.7%. MCK’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.1%.
McKesson’s shares have edged up 0.5% against the industry’s 1.6% decline in the year-to-date period.
Top Analyst-Rated Healthcare Stocks to Watch NowTenet Healthcare NYSE: THC raised its full-year 2026 financial outlook after reporting second-quarter results that exceeded its expectations, supported by hospital volume growth, higher-acuity services, expense-management efforts and continued strength in its ambulatory surgery business.
Second-quarter net operating revenues totaled $5.6 billion, while consolidated adjusted EBITDA rose 16.3% from a year earlier to $1.304 billion. Adjusted EBITDA margin was 23.2%, and adjusted diluted earnings per share increased 52% year over year to $6.12.
Get Tenet Healthcare alerts:
3 Under-the-Radar Healthcare CompaniesChairman and Chief Executive Officer Dr. Saum Sutaria said the company’s first-half fundamental outperformance totaled approximately $97 million across its operating segments. “Hospital volumes and same-store revenue growth in both segments are strong,” Sutaria said, adding that margin performance benefited from technology-enabled expense initiatives implemented at the beginning of the year.
Guidance Raised for Revenue, EBITDA and Cash Flow For 2026, Tenet increased its consolidated net operating revenue outlook to a range of $21.9 billion to $22.5 billion, representing a $300 million increase at the midpoint from its previous forecast. The company raised adjusted EBITDA guidance to $4.83 billion to $5.03 billion, a $295 million increase at the midpoint.
HCA Healthcare: Temporary Setbacks, Long-Term StrengthManagement said the revised EBITDA outlook reflects roughly $100 million in fundamental outperformance during the first half and another $60 million from the expected continuation of those drivers in the second half. The company also cited contributions from ambulatory surgery acquisitions and supplemental Medicaid programs.
Adjusted free cash flow after noncontrolling interests is now projected at $1.825 billion to $2.055 billion, up $225 million at the midpoint. That outlook includes roughly $150 million of tax payments related to the Conifer transaction. Excluding those payments, the midpoint would be approximately $2.1 billion, Chief Financial Officer Sun Park said.
Hospital Segment Outperforms Despite Exchange Pressure Tenet’s hospital segment generated $762 million in adjusted EBITDA, up 22% from the second quarter of 2025, with an 18% adjusted EBITDA margin. Same-hospital inpatient adjusted admissions increased 2.6%, while revenue per adjusted admission rose 3.3% year over year.
Park said the revenue-per-admission increase reflected the company’s acuity strategy and higher supplemental Medicaid revenue, partly offset by lower exchange volumes. The company recognized $92 million of favorable out-of-period supplemental Medicaid revenue tied to prior years, compared with $70 million in the prior-year quarter. Park said Tenet would have recorded a “clean beat” even without the incremental Medicaid revenue.
Exchange revenue declined 17% from the second quarter of 2025 and accounted for about 5.5% of consolidated revenue during the quarter. Exchange admissions fell about 13.5%, according to Park, resulting in an approximately $65 million revenue headwind.
Management said the exchange decline was most pronounced in Florida, Arizona, Michigan, South Carolina and Texas. Park said the company saw exchange patients shift to uninsured status at a rate that was “pretty much one-to-one,” with uninsured volume increasing proportionately in the second quarter.
Tenet expects the exchange-market trends seen in the second quarter to continue through the rest of 2026 and did not change its assumptions for the back half of the year. Sutaria said the company has been adjusting its cost base while maintaining investments in growth initiatives.
USPI Emphasizes Higher-Acuity Procedures United Surgical Partners International, Tenet’s ambulatory surgery business, reported adjusted EBITDA of $542 million, an 8.8% increase from the prior-year quarter. Its adjusted EBITDA margin was 39%.
USPI same-facility systemwide revenue rose 5%, including a 6.3% increase in net revenue per case. Same-facility case volume declined 1.2%, which management attributed to its focus on higher-acuity care and the migration of lower-acuity procedures to office settings.
Sutaria highlighted 10% year-over-year same-store growth in total joint replacements at the company’s ambulatory surgery centers. He said USPI continues to expand into higher-acuity orthopedic procedures as well as urology, robotics, bariatrics and cardiovascular services. The company is also pursuing more complex procedures in established gastrointestinal and ophthalmology service lines.
Tenet now expects to spend more than $300 million on ambulatory surgery center mergers and acquisitions during 2026, reflecting transactions completed so far and its current pipeline of opportunities.
Cost Management and Capital Deployment In response to analyst questions, Sutaria outlined several components of Tenet’s cost-management strategy. These include traditional productivity measures, renegotiating purchased-service contracts and supply standardization, as well as clinical operating improvements involving length of stay, emergency department service levels, hospital throughput and operating-room and catheterization-lab scheduling.
The company is also using automation, artificial intelligence and its global business center to improve productivity and automate certain functions across payment operations and support structures, Sutaria said.
Tenet generated $444 million in adjusted free cash flow during the second quarter and $1.422 billion year to date. As of June 30, it had $2.17 billion of cash on hand, no outstanding borrowings under its revolving credit facility and no significant debt maturities until late 2027.
The company repurchased 5.7 million shares for $1.04 billion during the second quarter. First-half share repurchases totaled nearly 7 million shares, costing $1.36 billion. Tenet’s board authorized a further $2 billion increase to its share repurchase program, and management said it expects to remain active in buybacks through the remainder of the year.
Tenet reported a leverage ratio of 2.33 times EBITDA as of June 30, or 2.9 times EBITDA excluding noncontrolling interests. Management said capital priorities include ambulatory surgery acquisitions, hospital investments focused on higher-acuity services, share repurchases and potential debt retirement or refinancing.
About Tenet Healthcare (NYSE:THC)Tenet Healthcare Corporation NYSE: THC is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet's operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.
In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Tenet Healthcare Right Now?Before you consider Tenet Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tenet Healthcare wasn't on the list.
While Tenet Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Both Eaton (ETN -1.76%)and nVent Electric (NVT -2.87%) are direct beneficiaries of the artificial intelligence (AI) data center and global electrification boom. Their revenue trajectories, however, reflect the contrast between an incumbent and a relatively smaller company trying to capture a bigger share of the market.
Eaton: A Steady Upward Revenue TrendEaton primarily generates revenue by providing energy-efficient solutions for electrical, hydraulic, and mechanical power across aerospace, vehicle, and other industrial segments.
While entering an agreement to separate its mobility group in June 2026, it reported a net margin of 12% for the quarter ended March 31, 2026.
nVent Electric: Consistent Quarter-Over-Quarter GainsnVent designs and produces electrical connection and protective equipment for commercial, industrial, and infrastructure applications.
It authorized a new share repurchase program and appointed new executive leadership in mid-2026, while reporting a net margin of 11% for the quarter ended March 31, 2026.
Why Revenue Matters for Retail InvestorsRevenue here refers to the data provider's standardized income statement revenue line item and serves as a baseline indicator of a company's ability to generate sales from its core business operations.
Quarterly Revenue for Eaton and nVent ElectricQuarter (Period End)Eaton RevenuenVent Electric RevenueQ2 2024 (June 2024)$6.3 billion$739.8 millionQ3 2024 (Sept. 2024)$6.3 billion$782.0 millionQ4 2024 (Dec. 2024)$6.2 billion$752.2 millionQ1 2025 (March 2025)$6.4 billion$809.3 millionQ2 2025 (June 2025)$7.0 billion$963.1 millionQ3 2025 (Sept. 2025)$7.0 billion$1.1 billionQ4 2025 (Dec. 2025)$7.1 billion$1.1 billionQ1 2026 (March 2026)$7.5 billion$1.2 billionData source: Company filings. Data as of July 13, 2026.
Foolish TakeEaton is a power management giant that designs and manufactures essential electrical distribution equipment, including transformers, circuit breakers, switchgear, substations, and uninterruptible power supply (UPS) systems. Its $9.5 billion acquisition of Boyd Thermal in March 2026 has given Eaton a huge headway into the rapidly growing liquid cooling market, creating one of the world’s largest grid-to-chip solutions providers.
Eaton’s revenue hit a record in Q1, with sales surging 17%, including 10% organic growth, 4% from Boyd and other acquisitions, and 3% from foreign exchange impact. Last quarter, Eaton raised its FY 2026 organic revenue guidance from 8% to 10% at the midpoint. Backlog as of the end of last quarter was $23 billion.
nVent Electric was spun off from Pentair (PNR +2.32%) in 2018 and has since doubled its sales. It does the work inside data centers, providing the electrical enclosures, cabinets, specialized racks, and thermal management solutions. Its steady revenue growth reflects strong demand.
nVent’s sales surged 51% year over year in Q1 to a record high, and it projects 2026 revenue growth of 26% to 28%. A backlog of $2.6 billion means nVent is almost 10 times smaller than Eaton, but it is growing faster. If you track the revenue trajectory, nVent could achieve higher percentage growth rates, as it’s a smaller company expanding its presence in data center cooling and connection infrastructure.
Look beyond the revenue growth, and both Eaton and nVent are solid AI plays right now.
Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. However, when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.
Cash flow can come from bond interest, interest from other types of investments, and, of course, dividends. A dividend is that coveted distribution of a company's earnings paid out to shareholders, and investors often view it by its dividend yield, a metric that measures the dividend as a percent of the current stock price. Many academic studies show that dividends account for significant portions of long-term returns, with dividend contributions exceeding one-third of total returns in many cases.
Based in Los Angeles, Cathay General (CATY - Free Report) is in the Finance sector, and so far this year, shares have seen a price change of 29.22%. The holding company for Cathay Bank is currently shelling out a dividend of $0.38 per share, with a dividend yield of 2.43%. This compares to the Banks - West industry's yield of 2.42% and the S&P 500's yield of 1.33%.
Looking at dividend growth, the company's current annualized dividend of $1.52 is up 11.8% from last year. Over the last 5 years, Cathay General has increased its dividend 1 times on a year-over-year basis for an average annual increase of 2.11%. Looking ahead, future dividend growth will be dependent on earnings growth and payout ratio, which is the proportion of a company's annual earnings per share that it pays out as a dividend. Cathay's current payout ratio is 31%, meaning it paid out 31% of its trailing 12-month EPS as dividend.
CATY is expecting earnings to expand this fiscal year as well. The Zacks Consensus Estimate for 2026 is $5.42 per share, which represents a year-over-year growth rate of 19.38%.
From greatly improving stock investing profits and reducing overall portfolio risk to providing tax advantages, investors like dividends for a variety of different reasons. However, not all companies offer a quarterly payout.
High-growth firms or tech start-ups, for example, rarely provide their shareholders a dividend, while larger, more established companies that have more secure profits are often seen as the best dividend options. Income investors have to be mindful of the fact that high-yielding stocks tend to struggle during periods of rising interest rates. That said, they can take comfort from the fact that CATY is not only an attractive dividend play, but is also a compelling investment opportunity with a Zacks Rank of #2 (Buy).
New York, New York--(Newsfile Corp. - July 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Primoris Services Corporation (NYSE: PRIM) between August 5, 2025 and June 22, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 21, 2026.
SO WHAT: If you purchased Primoris common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Primoris class action, go to https://rosenlegal.com/cases/primoris-services-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 21, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Primoris' cost estimation, cost-to-complete forecasting, and project oversight processes were deficient and failed to provide reliable estimates of the costs and expected profitability of significant fixed-price renewable energy projects; (2) as a result, Primoris systematically underestimated the costs and risks of significant fixed-price renewable energy projects that were experiencing material cost overruns, execution problems, and schedule delays; and (3) accordingly, defendants' statements regarding Primoris' estimating processes, project execution, ability to manage project risk, financial performance, and financial guidance lacked a reasonable basis and omitted material adverse facts. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Primoris class action, go to https://rosenlegal.com/cases/primoris-services-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/306431
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming September 21, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Primoris Services Corporation (“Primoris” or the “Company”) (NYSE: PRIM) common stock between August 5, 2025 and June 22, 2026, inclusive (the “Class Period”).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN PRIMORIS SERVICES CORPORATION (PRIM), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Past performance is not an indicator of future performance. This post is illustrative and educational and is not a specific offer of products or services or financial advice. Information in this article is not an offer to buy or sell or a solicitation of any offer to buy or sell the securities mentioned herein. Information presented is believed to be factual and up-to-date, but we do not guarantee its accuracy, and it should not be regarded as a complete analysis of the subjects discussed. Expressions of opinion reflect the judgment of the authors as of the date of publication and are subject to change.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Conagra Brands, Inc. remains a Buy, supported by a compelling portfolio, a strategic CEO transition, and an attractive valuation despite recent underperformance. The new CEO, John Brase, brings operational excellence and a clear mandate to simplify operations, raise prices, and focus on growth categories like frozen meals and meat snacks. The 50% dividend cut, while anticipated, strengthens CAG's balance sheet and supports long-term capital allocation priorities amid elevated leverage and margin pressures.
Shares of the language learning company Duolingo (DUOL +1.92%) fell by 9.8% this week, according to data provided by S&P Global Market Intelligence, as investors grow increasingly concerned about AI disruption.
Duolingo will report its second-quarter 2026 results early next month, and shareholders could be paring back their holdings now, in anticipation of a rough quarter.
Image source: The Motley Fool.
AI has Duolingo investors worried Duolingo's share price has nosedived over the past year, falling 66% as investors have become increasingly concerned that AI will disrupt Duolingo's business model.
Shareholders may have reacted this week to news that a yet-to-be-released OpenAI ChatGPT model went rogue and hacked a website. OpenAI was testing the model for its cybersecurity capabilities, and it broke free of its contained sandbox environment in search of the test answers.
Duolingo isn't a cybersecurity company, but its shareholders are already concerned that AI companies could disrupt the company's language learning and education app. A highly capable ChatGPT doesn't instill confidence that Duolingo can fend off AI competition.
Today's Change
(
1.92
%) $
2.32
Current Price
$
122.99
Shareholders may be bracing for Duolingo's quarterly results Duolingo is investing more in AI features to stay relevant, but it's coming at a cost. Management said gross margins will fall to 69% by the end of this year as AI-driven costs rise.
Duolingo has set a goal of 100 million daily active users in 2028 and is willing to sacrifice some higher margins to get there.
Investors will find out more about how well the company is achieving its goals when Duolingo reports its second-quarter results on Aug. 5. Still, it's clear from the share price declines this week that Duolingo has a lot to prove before regaining investor confidence.
Chris Neiger has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Duolingo. The Motley Fool has a disclosure policy.
The company reported adjusted earnings of 78 cents per share for the second quarter, beating the analyst consensus estimate of 74 cents. Revenue increased to $1.741 billion from a year earlier, exceeding the $1.70 billion consensus estimate.
Total sales rose 13.6% year over year, or 12.5% on a constant-currency basis.
TAVR, TMTT Businesses Fuel GrowthTranscatheter Aortic Valve Replacement (TAVR) sales increased 11.3% year over year, or 10.5% in constant currency, to $1.3 billion.
The company said procedural growth benefited from sustained clinical momentum and growing evidence supporting earlier treatment of severe aortic stenosis. Growth was similar in the U.S. and international markets and also benefited from a competitor’s market exit in 2025.
Transcatheter Mitral and Tricuspid Therapies (TMTT) revenue climbed to $195.9 million, supported by continued demand for the company’s repair and replacement therapies. Edwards said mitral and tricuspid procedure growth remained in the double digits globally.
Surgical segment sales rose 6.5% from a year earlier to $284 million, or 5% in constant currency. The increase was driven by continued adoption of the company’s RESILIA tissue technologies.
Company Raises Revenue OutlookEdwards reaffirmed its fiscal 2026 adjusted earnings guidance of $2.95 to $3.05 per share. That range brackets the Wall Street consensus estimate of $3.01.
The company also raised the low end of its full-year revenue guidance. It now expects revenue of $6.60 billion to $6.90 billion, up from its previous forecast of $6.50 billion to $6.90 billion. The updated range brackets the Wall Street consensus estimate of $6.745 billion.
Edwards also reaffirmed its expectation for 2026 TAVR sales of $4.75 billion to $5.0 billion.
Analyst Sees More Upside AheadWilliam Blair analyst Brandon Vazquez said Friday that the results reinforced the firm’s bullish outlook on Edwards.
“Overall, the second quarter reaffirmed our bullish thesis on Edwards shares, offering one of the better setups for medtech growth,” Vazquez wrote.
The analyst maintained an Outperform rating, saying the stock, trading at about 26 times projected 2027 earnings, could see further upside as earnings grow and additional catalysts emerge in the second half of 2026 and into 2027.
EW Stock Price Activity: Edwards Lifesciences shares were up 3.32% at $86.60 at the time of publication on Friday, according to Benzinga Pro data.
Market News and Data brought to you by Benzinga APIs
Key Takeaways Revvity is developing T-SPOT A201 for high-volume latent TB testing, targeting a late-2027 launch.The platform can process up to 384 samples in eight hours with 45 seconds of hands-on time per sample.RVTY shares rose 2.4% after the announcement and gained 16.9% year to date, beating key benchmarks. Revvity, Inc. (RVTY - Free Report) recently announced the development of the T-SPOT A201, a next-generation high-throughput automated platform designed to support large-volume clinical laboratories performing latent tuberculosis (TB) testing. Targeted for launch in the second half of 2027, the platform is engineered to deliver the performance advantages of the T-SPOT.TB assay while enabling greater workflow efficiency and scalability for high-throughput testing environments.
Per management, the T-SPOT A201 automation platform marks a significant advancement in expanding access to the benefits of T-SPOT.TB testing for high-volume laboratories. The company believes the solution will provide the performance, workflow efficiency and competitive economics needed by high-volume clinical labs, reinforcing its commitment to delivering scalable automation technologies for infectious disease diagnostics.
Likely Trend of RVTY Stock Following the NewsFollowing the announcement, RVTY shares gained 2.4% at yesterday’s close. Year to date, the stock rose 16.9%, outperforming the industry’s 1.8% decline and the S&P 500’s 7.4% gain.
The development of the T-SPOT A201 platform is expected to strengthen Revvity’s infectious disease diagnostics and laboratory automation portfolio. By addressing the growing need for high-throughput latent TB testing, the company can enhance its position among large clinical laboratories while expanding opportunities within public health and diagnostic markets. Upon successful commercialization, the platform could drive broader adoption of Revvity’s automation solutions, support long-term customer relationships and contribute to sustained revenue growth.
RVTY currently has a market capitalization of $12.33 billion.
Image Source: Zacks Investment Research
More on the NewsThe T-SPOT A201 expands Revvity’s portfolio of automation solutions that simplify the T-SPOT.TB workflow without compromising clinical performance. The company already offers the FDA-approved and CE-IVD-marked Auto-Pure 2400 liquid handler for laboratories with lower testing volumes. Designed to process up to 24 samples per run, the Auto-Pure 2400 completes first-day T-SPOT.TB workflows in less than 3.5 hours with minimal user interaction while delivering low indeterminate results, high sensitivity and specificity, extended sample stability and efficient sample handling. These capabilities enable laboratories of different sizes to improve workflow efficiency while maintaining confidence in latent TB test results.
Built on the success of the Auto-Pure 2400 liquid handling platform, the T-SPOT A201 is designed to process up to 384 samples per instrument during an eight-hour shift while requiring only 45 seconds of hands-on time per sample. The platform is expected to help laboratories manage rising testing volumes driven by immigration screening, pre-treatment evaluations for immunosuppressive therapies and broader public health initiatives, while supporting timely and accurate latent TB detection.
Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the U.S. tuberculosis diagnostics market is predicted to be valued at $607.5 million in 2026 and is expected to witness a CAGR of 5.3% through 2035.
Factors like the increasing adoption of rapid molecular and nucleic acid amplification tests, growing focus on detection of latent and drug-resistant tuberculosis, rising emphasis on automation, digital reporting and laboratory workflow efficiency and continued reliance on government funding and public health laboratory networks for TB testing programs are boosting the market’s growth.
Other NewsRevvity recently announced the launch of Signals for Startups, a new program to help early-stage biotechnology companies establish scalable digital informatics capabilities from the earliest stages of research. It is scheduled to launch across the United States, Europe, the Middle East and the Africa region in late July 2026.
Revvity announced that its Signals Software business has been added to Anthropic’s directory for Model Context Protocol connectors, extending the capabilities of Signals AI beyond the Signals One platform. Through the integration, scientists can access Signals AI and connected R&D knowledge using Claude, including Claude Science, Anthropic’s AI workbench for scientific research.
RVTY’s Zacks Rank & Key PicksRevvity currently carries a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , McKesson (MCK - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
West Pharmaceutical reported second-quarter 2026 adjusted earnings per share (EPS) of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
West Pharmaceutical has an estimated long-term earnings growth rate of 14.4%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
McKesson reported a fourth-quarter fiscal 2026 adjusted EPS of $11.69, which beat the Zacks Consensus Estimate by 1.1%. Revenues of $96.3 billion missed the Zacks Consensus Estimate by 5.5%.
McKesson has an estimated long-term earnings growth rate of 13.7%. MCK’s earnings surpassed estimates in the trailing four quarters, the average surprise being 3.1%.
Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.
Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.
New York, New York--(Newsfile Corp. - July 24, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Badger Meter, Inc. (NYSE: BMI) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Badger Meter securities between April 18, 2024 and April 16, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/BMI.
Badger Meter Case Details
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that:
the Company's reported strong financial results did not reflect "ongoing favorable industry trends," "secular growth drivers," or "solid operating execution," as represented, but were instead unsustainable; Defendants' statements touting "strong" demand, "robust order pacing," and a "strong bid pipeline" overstated the true state of the Company's demand environment and ability to generate continued sales and earnings growth; and contrary to Defendants' claims that the Company possessed a "long runway" for growth, the Company's growth prospects were materially overstated, such that Defendants lacked a reasonable basis for their positive statements about the Company's business, operations, and future prospects.What's Next for Badger Meter Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/BMI, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Badger Meter you have until August 3, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Badger Meter Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Badger Meter Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising.
Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300228
Source: Bronstein, Gewirtz & Grossman, LLC
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Key Takeaways MaxLinear's Q2 revenues rose 55% to $168.8 million as infrastructure sales surged 145%.MXL raised its 2026 optical data center outlook as 800G ramps and customer orders strengthened.MaxLinear expects Q3 revenues of $210-$220 million, with infrastructure leading growth again. MaxLinear (MXL - Free Report) reported second-quarter 2026 non-GAAP earnings of 35 cents per share, which beat the Zacks Consensus Estimate by 6.1%. The company reported earnings of 2 cents per share in the year-ago quarter.
Revenues of $168.8 million increased 55% and beat the consensus mark by 2.3%. Results benefited from accelerating adoption of optical AI data center products. Infrastructure revenues surged 145% year over year and remained the company’s largest revenue category.
MXL’s Infrastructure Business Drives GrowthInfrastructure revenues were $85 million in the second quarter, rising 35% sequentially. Growth was led by high-speed optical interconnects as production ramps broadened across data center-oriented platforms.
Keystone, MaxLinear’s 100-gigabit-per-lane PAM4 digital signal processor, continued ramping into high-volume production. MaxLinear said the latest revenue growth is increasingly driven by 800G deployments, with customers spanning U.S. and Asian hyperscalers, data center operators and equipment makers.
MaxLinear's Broadband and Connectivity Sales RiseBroadband revenues increased to $45 million, while connectivity revenues reached roughly $24 million. Industrial and multimarket revenues were about $15 million.
Broadband and connectivity gains reflected deployments of single-chip fiber PON and Wi-Fi 7 gateway platforms at major Tier 1 service providers in North America and Europe. MXL is also in the early stages of Ultra DOCSIS 3.1 and 4.0 deployments, which management expects to contribute as customer ramps progress through 2027 and 2028.
MXL’s New Wins Broaden AI ExposureThe company completed qualification of its first XGS-PON design win for a hyperscale data center control network. The program is expected to begin ramping in 2027.
MaxLinear also secured USB bridge controller design wins at two major hyperscalers for AI rack management. Its Panther storage accelerator family continued gaining traction, with management expecting revenues to roughly double in 2026 and potentially nearly double again in 2027.
MaxLinear Expands Optical Data Center ReachThe company raised its 2026 optical data center revenue expectations again, citing robust customer orders and stronger visibility into program ramps. Management said order visibility extends roughly six months, supporting confidence in second-half demand and the trajectory into 2027.
Rushmore, MaxLinear’s 1.6-terabit PAM4 platform operating at 200 gigabits per lane, is in customer qualification. Initial revenues are expected in 2027, with broader ramps anticipated through 2028 and 2029. Washington, a matching transimpedance amplifier and Annapurna, an electrical retimer platform, widen the company’s exposure to next-generation AI connectivity.
MXL’s Margins Show Operating LeverageNon-GAAP gross margin was 59.5% compared with 59.1% in the year-ago quarter.
Non-GAAP operating expenses were $62.8 million, up 11% year over year.
Non-GAAP operating margin expanded to 22.3% from 7.2%, reflecting the stronger infrastructure mix and higher revenues. Management expects infrastructure products to support further margin improvement. However, rising wafer, packaging and testing costs remain a headwind, with the company seeking to pass some increases to customers.
MaxLinear’s Balance Sheet Reflects Inventory BuildMaxLinear ended the quarter with $93.7 million in cash, cash equivalents and restricted cash.
Operating activities generated $4.8 million in cash, reversing the cash use recorded in the previous quarter.
Inventory rose to $105.5 million from $85.8 million sequentially as the company supported rising data center demand and secured wafer supply. Days of inventory improved to 123 from 128, while days sales outstanding edged up to 28 from 27.
MXL Guides to Strong Q3 GrowthFor the third quarter of 2026, MXL expects revenues between $210 million and $220 million. Management anticipates sequential growth across all four business categories, with infrastructure again leading on optical data center interconnect demand.
The company projects non-GAAP gross margin of 58.5-61.5% and non-GAAP operating expenses of $66-$71 million.
Zacks Rank & Stocks to ConsiderMaxLinear currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader Zacks Computer and Technology sector that are set to report their quarterly results are Amphenol (APH - Free Report) , Bandwidth (BAND - Free Report) and Fortinet (FTNT - Free Report) . Amphenol, Bandwidth and Fortinet sport a Zacks Rank #1 (Strong Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Amphenol, Bandwidth and Fortinet are set to report their second-quarter 2026 results on July 29. Year to date, shares of Amphenol, Bandwidth and Fortinet have returned 16.5%, 279.8% and 89.6%, respectively.
Deckers Outdoor (DECK) has reported a robust performance for Q1 (June), but the stock is down slightly following weaker-than-expected guidance for Q2 (Septembe
Green Plains Inc. (NASDAQ: GPRE) will release second quarter 2026 financial results prior to the market opening on August 6, 2026, and then host a conference ca
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Sensata (ST - Free Report) , which belongs to the Zacks Instruments - Control industry, could be a great candidate to consider.
This maker of sensing, electrical protection, control and power management products has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 2.35%.
For the last reported quarter, Sensata came out with earnings of $0.86 per share versus the Zacks Consensus Estimate of $0.84 per share, representing a surprise of 2.38%. For the previous quarter, the company was expected to post earnings of $0.86 per share and it actually produced earnings of $0.88 per share, delivering a surprise of 2.33%.
Price and EPS Surprise
With this earnings history in mind, recent estimates have been moving higher for Sensata. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank.
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Sensata has an Earnings ESP of +0.54% at the moment, suggesting that analysts have grown bullish on its near-term earnings potential. When you combine this positive Earnings ESP with the stock's Zacks Rank #2 (Buy), it shows that another beat is possibly around the corner. The company's next earnings report is expected to be released on July 29, 2026.
Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric.
Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.
Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
A month has gone by since the last earnings report for H. B. Fuller (FUL - Free Report) . Shares have lost about 11% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is H. B. Fuller due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important drivers.
Key highlightsH.B. Fuller logged earnings (as reported) of $1.23 per share for the second quarter of fiscal 2026 (ended May 30, 2026), compared with 76 cents reported a year ago.
Barring one-time items, adjusted earnings for the quarter were $1.41 per share, up 19% year over year. It beat the Zacks Consensus Estimate of $1.37.
The company posted revenues of $950.3 million, up around 6% year over year. It surpassed the Zacks Consensus Estimate of $927 million. Organic growth was up 2.6%.
Adjusted EBITDA was $181 million, up 9% year over year, with a margin of 19.1% versus 18.4% a year ago.
Revenue growth was driven by pricing and currency, offsetting modest volume weakness. Margin expansion in the quarter reflected realized pricing and Quantum Leap restructuring, partially offset by higher variable compensation and currency impacts.
Segment PerformanceHHC: Revenues were $421.9 million with organic revenue up 3% year over year. Adjusted EBITDA was $75.6M (up 22% y/y) with a margin of 17.9%, up 230 basis points (bps). Strength was seen in medical, tape & label and end-of-line packaging, offset by weak flexible packaging.
EA: Revenues were $283.2 million with organic growth of roughly 5% excluding solar exit. Aerospace was up 30% while electronics and general industries rose by double digits. Automotive declined by mid-single digits. Adjusted EBITDA was $63.5 million (flat year over year), with a margin of 22.4% (down 50 bps) due to higher variable comparisons.
BAS: Revenues were $245.2 million with organic growth of 6%. Adjusted EBITDA of $41.4 million rose 10% year over year with a margin of 16.9% (up 20 bps), led by glass and infrastructure/mechanical strength.
Cash Flow, Balance Sheet, Capital AllocationOperating cash flow was $121 million (a second-quarter record), supporting roughly 750,000 share repurchases in the quarter. Net leverage improved to 3.1x. Management continues Quantum Leap restructuring and Project ONE ERP, which are contributing to efficiency and margin gains.
GuidanceThe company expects fiscal 2026 (ex-AMS) net revenues to be up mid-single digits with organic growth of low single digits. Currency impacts are expected to be positive 1-2%.
Adjusted EBITDA is projected to be $650-$675 million. Adjusted earnings per share for fiscal 2026 are now forecast to be $4.60-$4.90.
Cash flow from operations for fiscal 2026 is expected to be in the range of $300 million to $325 million, weighted to the second half.
Net revenues for the fiscal third quarter are projected to rise mid-single digits. The company sees adjusted EBITDA of $180-$190 million for the quarter.
Management expects pricing in high-single-digits in the second half and volumes down low- to mid-single-digits. BAS is positioned for a stronger second half, EA is expected to improve as the solar exit laps, while HHC is more exposed to consumer softness. The proposed AMS acquisition is excluded from fiscal 2026 guidance.
How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a upward trend in estimates review.
VGM ScoresAt this time, H. B. Fuller has a subpar Growth Score of D, however its Momentum Score is doing a lot better with a B. Charting a somewhat similar path, the stock has a score of A on the value side, putting it in the top quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise H. B. Fuller has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Magnolia Oil & Gas Corp (MGY - Free Report) , which belongs to the Zacks Oil and Gas - Exploration and Production - United States industry, could be a great candidate to consider.
When looking at the last two reports, this company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 4.33%, on average, in the last two quarters.
For the most recent quarter, Magnolia Oil & Gas Corp was expected to post earnings of $0.51 per share, but it reported $0.54 per share instead, representing a surprise of 5.88%. For the previous quarter, the consensus estimate was $0.36 per share, while it actually produced $0.37 per share, a surprise of 2.78%.
Price and EPS Surprise
Thanks in part to this history, there has been a favorable change in earnings estimates for Magnolia Oil & Gas Corp lately. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the stock is positive, which is a great indicator of an earnings beat, particularly when combined with its solid Zacks Rank.
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Magnolia Oil & Gas Corp has an Earnings ESP of +4.28% at the moment, suggesting that analysts have grown bullish on its near-term earnings potential. When you combine this positive Earnings ESP with the stock's Zacks Rank #3 (Hold), it shows that another beat is possibly around the corner. The company's next earnings report is expected to be released on August 5, 2026.
When the Earnings ESP comes up negative, investors should note that this will reduce the predictive power of the metric. But, a negative value is not indicative of a stock's earnings miss.
Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.
Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
New York, New York--(Newsfile Corp. - July 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Planet Fitness, Inc. (NYSE: PLNT) between November 6, 2025 and May 6, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 14, 2026.
SO WHAT: If you purchased Planet Fitness common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Planet Fitness class action, go to https://rosenlegal.com/cases/planet-fitness-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 14, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or concealed material adverse facts concerning the true state of Planet Fitness' customer acquisition and marketing metrics. Notably, Planet Fitness' updated marketing messaging was failing to resonate with, and was actively intimidating, its core target demographic of fitness beginners and casual gym-goers. As a result, Planet Fitness was experiencing a significant headwind in net member joins during its peak first-quarter sign-up period that rendered its previously issued fiscal 2026 guidance and long term financial targets unachievable. Instead, Planet Fitness would be required to restructure its marketing strategy, losing the gains they praised from continuing the same marketing campaign, and entirely halt the planned Black Card price increase which sale projections were premised upon. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Planet Fitness class action, go to https://rosenlegal.com/cases/planet-fitness-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/306437
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming September 14, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Planet Fitness, Inc. (“Planet Fitness” or the “Company”) (NYSE: PLNT) common stock between November 6, 2025 and May 6, 2026, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR PLANET FITNESS INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIA.
Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Planet Fitness (PLNT - Free Report) , which belongs to the Zacks Leisure and Recreation Services industry.
This fitness center operator has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 11.26%.
For the most recent quarter, Planet Fitness was expected to post earnings of $0.63 per share, but it reported $0.74 per share instead, representing a surprise of 17.46%. For the previous quarter, the consensus estimate was $0.79 per share, while it actually produced $0.83 per share, a surprise of 5.06%.
Price and EPS Surprise
Thanks in part to this history, there has been a favorable change in earnings estimates for Planet Fitness lately. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the stock is positive, which is a great indicator of an earnings beat, particularly when combined with its solid Zacks Rank.
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Planet Fitness currently has an Earnings ESP of +3.37%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner. We expect the company's next earnings report to be released on August 6, 2026.
Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric.
Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.
Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
New York, New York--(Newsfile Corp. - July 24, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Planet Fitness, Inc. ("Planet Fitness" or the "Company") (NYSE: PLNT) on behalf of investors that purchased or otherwise acquired Planet Fitness securities between November 6, 2025 and May 6, 2026 (the "Class Period").
CLICK HERE TO JOIN THE CASE
If you are an investor in Planet Fitness and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.
DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than September 14, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.
The complaint alleges that defendants disseminated materially false and misleading statements and omissions concerning the true state of Planet Fitness' customer acquisition and marketing metrics. According to the complaint, the Company's updated marketing messaging was failing to resonate with, and was actively intimidating, its core target demographic of fitness beginners and casual gym-goers. As a result, according to the complaint, Planet Fitness was experiencing a significant headwind in net member joins during its peak first-quarter sign-up period that rendered its previously issued fiscal 2026 guidance and long term financial targets unachievable.
WHY CONTACT KAPLAN FOX?
Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.
Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.
For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.
If you have any questions about this Notice, your rights, or your interests, please contact:
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
Nobody -- and I mean nobody -- likes high interest rates. The average rate for a 30-year fixed mortgage is 6.55%, which is a huge difference from just five years ago, when rates were under 3%. And they don't appear to be headed down anytime soon.
But for investors, you can find a silver lining in bank stocks. That's because, while interest rates cause some pain for consumers, they can provide extra profits to banks and other lending institutions.
Banks make a portion of their money from the spread between what they pay depositors and what they earn by lending that money to consumers and businesses. When interest rates are up, as they are now, banks can charge more for mortgages, credit cards, vehicle loans, and commercial loans. That potentially means more net income for the bank and greater profits when banks report quarterly earnings.
Three interesting bank stocks to consider in July's high-interest rate environment are Bank of America (BAC +1.11%), PNC Financial Services (PNC +0.60%), and SoFi Technologies (SOFI -0.33%).
Image source: Getty Images.
Bank of America: The big bank Bank of America is one of the biggest banks in the U.S., with more than 3,600 banking locations and 15,000 ATMs. The bank offers consumer, business, and wealth management services -- all divisions that saw solid growth in the second quarter. Every division recorded double-digit net income growth, CEO Brian Moynihan said.
Bank of America reported that it added 160,000 net new checking accounts, opened 1 million new credit card accounts, and its customer investment and wealth management balances rose 12% from a year ago to $4.9 trillion.
Today's Change
(
1.11
%) $
0.68
Current Price
$
61.96
Revenue in the second quarter was $31.6 billion, up 15.3% from a year ago. Net income of $9.1 billion was up 26.4%, and earnings per share improved from $0.84 to $1.21.
Bank of America is one of the best big bank stocks you can buy, and its dividend of 1.8% contributes to a total return of 12.5% so far this year.
PNC Financial Services Group: The regional bank PNC is still considered a regional bank, but if it keeps expanding, the market may need to reconsider that designation. The Pittsburgh-based company has a broad reach -- it has locations coast-to-coast, operating 2,300 branches. In January, PNC completed its $4.1 billion acquisition of FirstBank, which allowed it to add nearly 100 branches in Arizona and Colorado as it seeks to gain a larger foothold in the western U.S.
Second-quarter earnings showed revenue of $6.87 billion, up from $5.66 billion a year ago. Net income was $2.05 billion, up from $1.64 billion, and earnings per share were $4.81 versus $3.85 a year ago.
Today's Change
(
0.60
%) $
1.49
Current Price
$
250.75
The dividend yield is currently 3.2%, helping push the stock to a 22.8% overall gain in 2026.
SoFi Technologies: Down, but not out SoFi stock is down more than 30% so far this year, having taken a solid beating when management chose not to increase guidance in its first-quarter earnings report. But it has a compelling story.
SoFi is a different kind of bank, operating as an online-only institution while also providing personal loans, mortgages, investments, and credit card services. Its customers also have access to more than 55,000 ATMs at no charge.
Today's Change
(
-0.33
%) $
-0.06
Current Price
$
16.60
SoFi still hasn't issued its Q2 results -- that won't happen until July 29. But in the first quarter, SoFi reported more-than-solid results, with revenue of $1.1 billion, up 43% from a year ago, net income of $155.7 million, up 134%, and earnings per share doubling from $0.06 to $0.12 per share.
If SoFi has another solid quarter and, this time, raises guidance, SoFi stock will be poised to close the month on a high note.
Investors interested in Electronics - Miscellaneous Components stocks are likely familiar with TE Connectivity (TEL) and Vishay Precision (VPG). But which of these two stocks presents investors with the better value opportunity right now?
MarketBeat’s Top-Rated Dividend Stocks for 2026Glacier Bancorp NYSE: GBCI reported second-quarter net income of $97.9 million, up 19% from the prior quarter and 85% from a year earlier, as net interest income and margin expansion supported earnings growth.
Diluted earnings per share totaled $0.75, increasing 19% sequentially and 67% year over year. President and CEO Randall Chesler said the company’s tax-equivalent net interest margin expanded to 3.90%, up 10 basis points from the first quarter and 69 basis points from the second quarter of 2025.
Get Glacier Bancorp alerts:
Net interest income rose 3% from the first quarter and 33% from the prior-year period to $276 million. Pretax, pre-provision net revenue was $130.8 million, rising 23% sequentially and 53% year over year.
Funding Costs Decline, Deposit Base Remains Stable Glacier’s total cost of funding declined to 1.33%, down 7 basis points from the first quarter and 30 basis points from a year ago. Core deposit costs, including noninterest-bearing deposits, were 1.18%, down 2 basis points sequentially. Noninterest-bearing deposits represented 30% of total deposits, unchanged from both the preceding quarter and the year-earlier period.
Treasurer Byron Pollan said the June 30 deposit cost was also 1.18% and said deposit costs should remain stable if the Federal Reserve holds interest rates steady.
“I think competition is strong. It always is. It’s rational,” Pollan said in response to a question about deposit competition. Chesler added that Glacier’s footprint is about 75% rural and 25% urban, and said the company’s emphasis on core customer relationships contributes to its lower-cost funding profile.
Average deposits were $24.5 billion during the second quarter, up $112 million from the first quarter on a 2% annualized basis. Period-end deposits were $24.7 billion, down slightly from the prior quarter. Chesler said deposit levels remained stable and continued to support the company’s liquidity and funding strategy.
Loan Growth Broad-Based Across Operating Regions Loans ended the quarter at $21.4 billion, increasing $330 million from the first quarter, or 6% on an annualized basis. Chesler described growth as broad-based and attributed it to disciplined production in attractive markets.
The company operates across Southwest and Mountain West regions. Chesler said the Southwest continued to perform well and was rebuilding its pipeline after a strong first quarter, while the Mountain West posted a strong second quarter.
Chief Credit Administrator Tom Dolan said the second and third quarters have generally been the company’s stronger seasonal lending periods. He said loan pipelines remained healthy, with continued pull-through and back-build activity, as well as tailwinds from construction draws and the agricultural growth season.
Glacier continued to generate new loan production yields above 6.5% during the quarter, Dolan said. He characterized pricing as the primary competitive factor, particularly in larger metropolitan markets, while saying the company had not observed substantial competitive pressure on underwriting discipline or loan structure.
Margin Expected to Reach 4% in Fourth Quarter Pollan said Glacier expects its net interest margin to continue expanding and anticipates reaching a 4% margin level early in the fourth quarter of 2026. He said the company expects to exit 2026 with a margin above 4%.
He noted that certain second-quarter headwinds, including nonaccrual interest reversals and lower accretion, appeared elevated and were not expected to persist at the same level. Pollan said the level of discount accretion reported in the second quarter was likely a more normal assumption going forward.
Over the longer term, Pollan said he views Glacier’s margin as potentially ranging between 4% and 4.5%, its more historical norm. He said a steeper yield curve and continued meaningful loan growth could help move the margin toward the upper end of that range, and he expects margin expansion to continue through 2027.
The company also resumed some investment securities purchases during the quarter, buying approximately $250 million of bonds. Pollan said Glacier expects to continue putting cash to work and anticipates average earning assets will increase in the third and fourth quarters following the completion of Federal Home Loan Bank advance paydowns.
Credit Remains Stable; Expense Guidance Unchanged Chesler said credit quality remained excellent. Early-stage delinquencies declined from the first quarter, while nonperforming assets increased modestly but remained low relative to subsidiary assets. The allowance for credit losses stood at 1.22% of total loans.
Dolan said credit trends were stable overall, with no particular industry, geography or asset class showing outsized risk. He said the company continues to monitor its agricultural portfolio, though 2025 performed better than anticipated and 2026 has started well.
Acquisition-related expenses declined meaningfully during the quarter, helping improve Glacier’s operating efficiency ratio to 56.21% from 63.05% in the first quarter. Chief Financial Officer Ron Copher maintained quarterly expense guidance of $187 million to $192 million for the second half, noting that some discretionary spending could return.
For the first half of 2026, Glacier reported net income of $180 million, up 68% from the prior-year first half, while diluted earnings per share increased 48% to $1.38. The board declared a quarterly dividend of $0.33 per share, marking the company’s 165th consecutive quarterly dividend, according to Chesler.
On capital management, Pollan said the company’s capital position was strong and would continue to grow with earnings. He said management was evaluating its outlook for capital accumulation and retained flexibility regarding potential capital-return options.
About Glacier Bancorp (NYSE:GBCI)Glacier Bancorp, Inc is a bank holding company headquartered in Kalispell, Montana. Through its network of community banks, the company delivers commercial and retail banking services to individuals, small and medium-sized businesses, and agricultural clients. With a commitment to relationship-driven banking, Glacier Bancorp combines local market expertise with regional scale to offer customized financial solutions that address the unique needs of the communities it serves.
Established in 1955 as Glacier Bank, the company has expanded both organically and through targeted acquisitions to build a presence across the Mountain West and into the Upper Midwest and Southwest.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Glacier Bancorp Right Now?Before you consider Glacier Bancorp, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Glacier Bancorp wasn't on the list.
While Glacier Bancorp currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.
"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
New York, New York--(Newsfile Corp. - July 24, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against The Simply Good Foods Company ("Simply Good" or the "Company") (NASDAQ: SMPL).
CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION
If you are a Simply Good investor and have suffered losses, or if you have information that could assist in the Simply Good investigation, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.
On June 13, 2024, Simply Good announced the completion of the acquisition of Only What You Need (OWYN) for a purchase price of $280 million.
On October 23, 2025, Simply Good reported financial results for the fourth quarter of 2025, disclosing among other things, a "quality issue" with the Company's recently acquired OWYN brand, "related to a raw material sourcing decision for pea protein made prior to the closing of the acquisition."
Following this news, the price of Simply Good stock fell $4.33 per share, or 17.35%, to close at $20.63 per share on October 23, 2025
Then, on April 9, 2026, Simply Good reported financial results for the second quarter of 2026, including that "Net sales of $326.0 million decreased 9.4% versus the comparable year ago period, driven by declines for Atkins and OWYN of 26.6% and 16.8%, respectively." Simply Good also "recognized an aggregate $249.0 million non-cash, impairment charge related to the Atkins brand and OWYN brand intangible assets" comprised of "a loss on impairment $187.0 million for OWYN and $62.0 million for Atkins[.]"
Following this news, the price of Simply Good stock fell $2.61 per share, or 18.11%, to close at $11.80 per share on April 9, 2026.
WHY CONTACT KAPLAN FOX?
Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.
Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.
For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.
If you have any questions about this investigation, please contact:
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL - Free Report) and Illumina (ILMN - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.
Currently, both Exelixis and Illumina are holding a Zacks Rank of #2 (Buy). Investors should feel comfortable knowing that both of these stocks have an improving earnings outlook since the Zacks Rank favors companies that have witnessed positive analyst estimate revisions. But this is just one piece of the puzzle for value investors.
Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.
Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.
EXEL currently has a forward P/E ratio of 15.74, while ILMN has a forward P/E of 37.74. We also note that EXEL has a PEG ratio of 1.43. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. ILMN currently has a PEG ratio of 2.91.
Another notable valuation metric for EXEL is its P/B ratio of 7.23. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, ILMN has a P/B of 11.13.
Based on these metrics and many more, EXEL holds a Value grade of B, while ILMN has a Value grade of C.
Both EXEL and ILMN are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that EXEL is the superior value option right now.
Investors with an interest in Transportation - Truck stocks have likely encountered both Werner Enterprises (WERN) and XPO (XPO). But which of these two companies is the best option for those looking for undervalued stocks?
The market expects CBOE Global (CBOE - Free Report) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
The earnings report, which is expected to be released on July 31, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus EstimateThis holding company for the Chicago Board Options Exchange is expected to post quarterly earnings of $3.41 per share in its upcoming report, which represents a year-over-year change of +38.6%.
Revenues are expected to be $708.54 million, up 20.6% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.9% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for CBOE?For CBOE, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +1.83%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination indicates that CBOE will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that CBOE would post earnings of $3.37 per share when it actually produced earnings of $3.70, delivering a surprise of +9.79%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
CBOE appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Expected Results of an Industry PlayerAnother stock from the Zacks Securities and Exchanges industry, IntercontinentalExchange (ICE - Free Report) , is soon expected to post earnings of $1.84 per share for the quarter ended June 2026. This estimate indicates a year-over-year change of +1.7%. Revenues for the quarter are expected to be $2.63 billion, up 3.3% from the year-ago quarter.
The consensus EPS estimate for ICE has been revised 2% lower over the last 30 days to the current level. However, an equal Most Accurate Estimate has resulted in an Earnings ESP of 0.00%.
This Earnings ESP, combined with its Zacks Rank #3 (Hold), makes it difficult to conclusively predict that ICE will beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.
Below, we take a look at Quest Diagnostics (DGX - Free Report) , a company that currently holds a Momentum Style Score of B. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score.
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Quest Diagnostics currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.
You can see the current list of Zacks #1 Rank Stocks here >>>
Set to Beat the Market?Let's discuss some of the components of the Momentum Style Score for DGX that show why this medical laboratory operator shows promise as a solid momentum pick.
A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.
For DGX, shares are up 1.56% over the past week while the Zacks Medical - Outpatient and Home Healthcare industry is up 1.41% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 10.5% compares favorably with the industry's 7.08% performance as well.
While any stock can see its price increase, it takes a real winner to consistently beat the market. That is why looking at longer term price metrics -- such as performance over the past three months or year -- can be useful as well. Shares of Quest Diagnostics have increased 17.35% over the past quarter, and have gained 32.58% in the last year. On the other hand, the S&P 500 has only moved 4.48% and 17.65%, respectively.
Investors should also pay attention to DGX's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. DGX is currently averaging 1,013,849 shares for the last 20 days.
Earnings OutlookThe Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with DGX.
Over the past two months, 1 earnings estimate moved higher compared to none lower for the full year. This revision helped boost DGX's consensus estimate, increasing from $10.70 to $10.72 in the past 60 days. Looking at the next fiscal year, 1 estimate has moved upwards while there have been no downward revisions in the same time period.
Bottom LineGiven these factors, it shouldn't be surprising that DGX is a #2 (Buy) stock and boasts a Momentum Score of B. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep Quest Diagnostics on your short list.
Key Takeaways Harley-Davidson's Q2 EPS beat estimates as HDMC revenues rose 6% on stronger motorcycle demand.North American retail sales grew 3%, marking a third straight quarter of year-over-year growth.HOG raised 2026 motorcycle sales and HDMC profit outlooks, while HDFS also lifted its income forecast. Harley-Davidson, Inc. (HOG - Free Report) reported second-quarter 2026 earnings of 75 cents per share, beating the Zacks Consensus Estimate of 62 cents by 21%. Earnings declined 15% from 88 cents a year ago. Harley-Davidson Motor Company revenues increased 6% year over year to $1.10 billion but missed the Zacks Consensus Estimate of $1.12 billion. Consolidated revenues fell 6% year over year to $1.23 billion as a sharp decline at Harley-Davidson Financial Services offset growth at the motorcycle business.
HOG Benefits From Stronger Motorcycle DemandMotorcycle revenues advanced 9% to $848 million, supported by higher shipments. Apparel and licensing revenues rose 2% to $62 million, while parts and accessories revenues declined 5% to $177 million.
Worldwide motorcycle shipments increased 9% to 39,209 units. Touring shipments rose 9%, cruiser shipments increased 3% and Sport and Lightweight shipments surged 45%. Adventure Touring shipments declined 4% from the prior-year quarter.
Harley-Davidson Retail Sales Rise in North AmericaWorldwide retail motorcycle sales increased 1% to 42,467 units. North American retail sales rose 3% to 29,751 units, marking the third consecutive quarter of year-over-year growth in the company’s core market. Strength in Touring and Sport models and favorable reception for the redesigned 2026 Trike lineup supported demand.
International performance remained mixed. EMEA retail sales fell 9%, reflecting weakness in the German region. Asia-Pacific sales were roughly flat, with growth in Australia and New Zealand offsetting a decline in Japan. Latin American retail sales increased 4%, aided by gains in Mexico.
HOG Posts Improved HDMC Operating ProfitHDMC gross profit increased 2% to $304 million, but gross margin contracted 108 basis points to 27.5%. Favorable manufacturing and other costs, including a tariff recovery, were offset by unfavorable product mix, net pricing, raw-material costs and foreign-currency effects.
Operating expenses declined 2% to $232 million despite $3 million of restructuring costs. HDMC operating income rose 18% to $72 million, while operating margin expanded 68 basis points to 6.6%. Adjusted EBITDA increased 18% to $115 million, producing a margin of 10.4% compared with 9.3% a year earlier.
Harley-Davidson Financial Services Results FallHDFS revenues declined 55% year over year to $117 million, primarily because of lower retail finance receivable balances following loan-asset sales completed in the second half of 2025. Interest income fell 72%, while other income increased 33% on favorable servicing fees.
Operating income decreased 69% to $22 million, and operating margin contracted to 18.5% from 27.1%. Lower interest expense and credit-loss provisions partly offset the reduced revenue base. Total retail loan originations increased 10%, while the managed retail credit-loss ratio improved to 3% from 3.3%.
HOG’s LiveWire Loss Narrows on Higher SalesLiveWire revenues rose 52% to $9.1 million, driven by increased electric motorcycle volumes and higher STACYC electric balance bike sales. Consolidated unit sales advanced 10% to 5,269 units during the quarter.
The segment’s operating loss narrowed to $17.9 million from $18.7 million. Higher revenues and lower selling, administrative and engineering expenses supported the improvement, partly offset by increased cost of goods sold. LiveWire also commenced production of the S4 Honcho and completed its acquisition of Dust Motorcycles in May.
Harley-Davidson’s Financial Position & Capital ReturnsAs of June 30, 2026, Harley-Davidson had cash and equivalents of $1.90 billion compared with $3.1 billion as of Dec. 31, 2025. It returned $50 million to shareholders during the quarter through $30 million of discretionary share repurchases and $20 million of dividends. For the first six months of 2026, operating cash outflow totaled $59 million and free cash outflow was $104 million.
HOG Raises Its 2026 OutlookHarley-Davidson raised its full-year projection for global motorcycle retail sales and wholesale shipments to 133,500-138,500 units from the previous estimate of 130,000-135,000 units. HDMC operating income is now expected between $10 million and $50 million compared with the earlier expected range of a $40 million loss to a $10 million profit.
HDFS operating income is projected at $55-$70 million, up from the prior forecast of $45-$60 million. The company maintained its expectation for a LiveWire operating loss of $70-$80 million and capital investments of $175-$200 million.
HOG currently carries a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Key Releases From Auto SpaceGeneral Motors Company (GM - Free Report) reported second-quarter 2026 adjusted earnings of $3.57 per share, up 41.3% year over year. The figure beat the Zacks Consensus Estimate of $3.13 by 14.06%. Revenues increased 1.9% to $48.03 billion and surpassed the consensus estimate of $46.56 billion by 3.15%. Strong pricing, lower costs and disciplined incentives supported results. General Motors raised its full-year adjusted EBIT guidance to $14-$16 billion from $13.5-$15.5 billion. Adjusted earnings are now projected at $12-$14 per share, up from the prior range of $11.50-$13.50.
Tesla, Inc. (TSLA - Free Report) reported second-quarter 2026 adjusted earnings of 33 cents per share, which declined 17.5% year over year. The figure missed the Zacks Consensus Estimate of 50 cents by 34%. Revenues advanced 25.5% to $28.24 billion and surpassed the consensus estimate of $25.81 billion by 9.41%. Tesla expects 2026 capital expenditures to exceed $25 billion and rise further over the next two to three years.
Genuine Parts (GPC - Free Report) reported second-quarter 2026 adjusted earnings of $2.15 per share, beating the Zacks Consensus Estimate of $2.10 by 2.38%. The bottom line increased 2.4% from $2.10 in the year-ago quarter. Revenues rose 6% year over year to $6.54 billion and surpassed the consensus estimate of $6.39 billion by 2.36%. Genuine Parts reaffirmed its 2026 adjusted earnings guidance of $7.50-$8 per share and total sales growth outlook of 3-5.5%. Genuine Parts ended June with $2.3 billion of liquidity, including $559 million in cash.
Investors interested in Retail - Restaurants stocks are likely familiar with BJ's Restaurants (BJRI - Free Report) and Shake Shack (SHAK - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.
Currently, BJ's Restaurants has a Zacks Rank of #2 (Buy), while Shake Shack has a Zacks Rank of #5 (Strong Sell). The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that BJRI has an improving earnings outlook. But this is only part of the picture for value investors.
Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
BJRI currently has a forward P/E ratio of 29.22, while SHAK has a forward P/E of 49.56. We also note that BJRI has a PEG ratio of 2.09. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. SHAK currently has a PEG ratio of 4.33.
Another notable valuation metric for BJRI is its P/B ratio of 3.67. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, SHAK has a P/B of 4.32.
These metrics, and several others, help BJRI earn a Value grade of B, while SHAK has been given a Value grade of D.
BJRI has seen stronger estimate revision activity and sports more attractive valuation metrics than SHAK, so it seems like value investors will conclude that BJRI is the superior option right now.
Surgery Partners Sells Idaho Falls Facilities To IntermountainThe surgical services provider is set to sell its ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health for approximately $795 million, with the total valuation of the facilities at about $1.15 billion.
“For Surgery Partners, assuming physician partner approval, this transaction represents the largest step forward in our portfolio optimization strategy to date, simplifying our go-forward operations, and positioning us to accelerate momentum in the rapidly growing, high-value ambulatory surgery center space,” said Eric Evans, CEO of Surgery Partners.
The company reaffirmed its fiscal 2026 revenues to be between $3.35 billion and $3.45 billion compared to the consensus of $3.408 billion, and adjusted EBITDA of at least $530 million.
SGRY Technical Analysis: Trend, Support And ResistanceFrom a technical perspective, SGRY is experiencing a bullish trend, with the stock currently trading 1.1% below its 20-day simple moving average (SMA) of $16.26.
The 50-day SMA sits 7.5% above the current price, potentially creating resistance at that level.
The Relative Strength Index (RSI) is at 53.11, suggesting that the stock is in a neutral zone, indicating neither overbought nor oversold conditions. This positioning allows for further upward momentum if the stock can break through key resistance levels.
Key Resistance: $16.50 — a nearby level where rebounds can stall. Key Support: $13.50 — a level where buyers previously stepped in. SGRY Earnings Preview And Analyst OutlookSurgery Partners will report its next financial update on August 10, 2026.
EPS Estimate: 4 cents (Down from 17 cents) Revenue Estimate: $831.33 Million (Up from $826.20 Million) How Surgery Partners Ranks On Value, Growth And MomentumBelow is the Benzinga Edge scorecard for Surgery Partners, highlighting its strengths and weaknesses compared to the broader market:
Value: Weak (Score: 11.41) — Trading at a steep premium relative to peers. Growth: Weak (Score: 4.31) — Limited growth indicators in the current environment. Momentum: Weak (Score: 18.2) — Stock is underperforming the broader market. SGRY Stock Price Activity: Surgery Partners shares were up 6.31% at $16.18 at the time of publication on Friday, according to Benzinga Pro data.
Image via Shutterstock
Market News and Data brought to you by Benzinga APIs
Key Takeaways MAA is expected to report Q2 revenue growth, while core FFO per share is projected to decline year over year.MAA cited steady occupancy, strong renewals and improving lease trends entering Q2.MAA guided Q2 core FFO to $2.00-$2.12 per share as higher costs may partly offset operating stability. Mid-America Apartment Communities (MAA - Free Report) — commonly known as MAA — is a real estate investment trust (REIT) that focuses on owning, operating and acquiring apartment communities throughout the Southeast, Southwest and Mid-Atlantic regions of the United States. The company is slated to report second-quarter 2026 results on July 29, after market close.
In the last reported quarter, this Germantown, TN-based residential REIT reported core FFO per share of $2.13, delivering a surprise of 0.47%. Results reflected same-store effective blended lease rate growth year over year.
Over the trailing four quarters, MAA surpassed the Zacks Consensus Estimate on three occasions and missed on the other, the average beat being 0.23%. This is depicted in the chart below:
Let’s see how things have shaped up before this announcement.
US Apartment Market in Q2The U.S. multifamily market entered the second half of 2026 with a clearer recovery taking shape, as strong renter demand and a rapidly shrinking supply pipeline began translating into lower vacancy and improving rent growth.
According to a Cushman & Wakefield report, net absorption reached roughly 124,600 units, up from 83,500 units in the first quarter and 8% above the prior year, making it the fifth-strongest quarter in nearly 25 years. The supply picture also became more favorable. Approximately 88,000 units were delivered during the quarter, down 27% year over year. Around 475,000 units remained under construction at quarter-end, equal to just 3.5% of existing inventory.
Improving demand and slowing supply pushed the national vacancy rate down 35 basis points quarter over quarter to 8.9%, its first move below 9% since 2024. On a trailing four-quarter basis, absorption of approximately 362,000 units exceeded deliveries of about 358,000 units for the first time since early 2022, indicating vacancy is likely to have passed its cyclical peak. The recovery was particularly pronounced in previously overbuilt markets: Austin; Charleston, SC; Savannah, GA; Huntsville, AL; Salt Lake City, UT, and Colorado Springs recorded some of the largest quarterly vacancy declines.
Rent growth remains modest but is beginning to improve. National asking rents reached approximately $1,945 per month, up 1.5% year over year, compared with 1.1% growth in the first quarter. The Bay Area led the recovery, with San Francisco rents rising 13%, San Jose 7% and the East Bay 4.8%. Norfolk, VA; Toledo, OH; Reno, NV; and Boise, ID, also posted strong gains.
High-supply markets remained softer, with rents still declining in Austin and Sarasota, FL, although the pace of those declines moderated as excess supply was absorbed. Overall, the market appears to be shifting from stabilization into an occupancy-led recovery, with broader rent growth likely as the construction pipeline continues to shrink.
Factors to Consider Ahead of MAA’s Upcoming ResultsMAA’s second-quarter 2026 results should reflect continued operating stability, with renewals, occupancy and moderating supply pressure supporting performance. Management said renewal growth remained above 5% entering the quarter, while April physical occupancy held at 95.5% and 60-day exposure improved 20 basis points from a year earlier. The company expects blended lease growth to accelerate from the first quarter’s negative 0.3%, helped by steady renewals and a more normal seasonal improvement in new lease pricing through July.
New lease rates will likely remain the main swing factor. Management noted improving momentum in March and April and expects May and June to perform better than last year, supported by strong lead volume, positive absorption and fewer deliveries. Atlanta and Dallas are showing better pricing and occupancy trends, while Austin, Charlotte and Savannah, GA, remain pressured by elevated concessions and supply.
For the quarter, MAA guided core FFO to $2.00-$2.12 per share, with a midpoint of $2.06. Higher seasonal maintenance costs and increased interest expense are likely to have limited the upside, although property dispositions and disciplined expense control may have partly offset those pressures.
Projections for MAAThe Zacks Consensus Estimate for quarterly revenues is pegged at $557.28 million. This suggests a 1.34% rise from the year-ago quarter’s reported figure.
For the second quarter, we project an average physical occupancy of 95.6%. However, we expect same-store property net operating income to fall 1.3% year over year. Our estimate indicates a 16.5% increase in the company’s interest expenses.
Before the second-quarter earnings release, the company’s activities were not adequate to gain analysts’ confidence. The Zacks Consensus Estimate for the quarterly core FFO per share has remained unchanged at $2.08 for more than two months. This also suggests a year-over-year decline of 3.26%.
Here Is What Our Quantitative Model Predicts for MAAOur proven model does not conclusively predict a surprise in terms of FFO per share for MAA this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an FFO beat, which is not the case here.
MAA currently carries a Zacks Rank of 3 and has an Earnings ESP of -0.20%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks That Warrant a LookHere are two stocks from the broader REIT sector — Extra Space Storage (EXR - Free Report) and Cousins Properties (CUZ - Free Report) — you may want to consider, as our model shows that these have the right combination of elements to report an FFO beat this quarter.
Extra Space Storage is slated to report quarterly numbers on July 28. EXR has an Earnings ESP of +0.39% and a Zacks Rank of 3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cousins is slated to report quarterly numbers on July 30. CUZ has an Earnings ESP of +0.45% and a Zacks Rank of 3 at present.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO), a widely used metric to gauge the performance of REITs.
Shelton, CT, July 24, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Hubbell Incorporated (NYSE:HUBB) today declared a regular quarterly dividend of $1.42 per share on the Company's common stock. The dividend will be paid on September 15, 2026 to shareholders of record on August 31, 2026.
New York, New York--(Newsfile Corp. - July 24, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Helen of Troy Limited (NASDAQ: HELE) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Helen of Troy securities between April 24, 2024 and October 8, 2025, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/HELE.
Helen of Troy Case Details
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that:
Helen of Troy overstated the success and benefits of its Project Pegasus initiative, touting the "fuel" it was generating while downplaying issues such as "implementation hiccups" at its Tennessee distribution center and assuring investors that the project was progressing and delivering cost-saving efficiencies; in reality, Project Pegasus was not delivering the efficiencies Defendants claimed, as the Company lacked sufficient resources and budget to achieve its stated restructuring and cost-savings goals; and as a result, Defendants' statements about the Company's business, operations, and prospects were materially false and misleading at all relevant times.What's Next for Helen of Troy Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/HELE, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Helen of Troy you have until August 3, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Helen of Troy Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Helen of Troy Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising.
Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300155
Source: Bronstein, Gewirtz & Grossman, LLC
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Investors interested in stocks from the Retail - Apparel and Shoes sector have probably already heard of Urban Outfitters (URBN) and Ermenegildo Zegna N.V. (ZGN). But which of these two stocks is more attractive to value investors?
SpaceX (NASDAQ:SPCX | SPCX Price Prediction) stock is sinking 5% Friday to $112.59, leaving the rocket maker 17% below its $135 June IPO price. The stock is sliding just hours before Starship attempts its 13th test flight tonight, a launch that could determine whether SpaceX’s costly pivot away from Falcon 9 pays off.
Rocket Lab (NASDAQ:RKLB) stock is falling harder, down 7% to $65.27, while AST SpaceMobile (NASDAQ:ASTS) stock is slipping 4% to $56.94. Neither company faces a company-specific catalyst today, and the selling looks more like a sympathy trade tied to SpaceX’s own troubles than a verdict on either business.
SpaceX’s Big Bet on Tonight’s Starship Test SpaceX has reportedly stopped taking new Falcon 9 bookings for dedicated satellite launches beyond 2028 and isn’t accepting reservations for its Falcon 9 rideshare program. The company has also reportedly halted production of some non-reusable Falcon hardware, including the upper stage that carries cargo, while Falcon 9 continues to support certain NASA and U.S. Department of Defense missions.
Tonight marks Starship’s third launch attempt in nine days, following a July 16 engine abort and a weather scrub last Thursday, with the window opening at 6:45 p.m. EDT at Starbase, Texas. A successful flight would be the first real validation of the reusability plan underpinning SpaceX’s push to retire Falcon 9, while another setback would deepen doubts about that timeline.
Rocket Lab and AST SpaceMobile Get Caught in the Downdraft AST SpaceMobile raised $1.15 billion through convertible notes to fund growth and secure launch capacity, a move that underscores how dependent the company remains on SpaceX. SpaceX has launched most of AST SpaceMobile’s satellite fleet and is expected to carry its next batch, even though SpaceX’s own Starlink network competes with AST SpaceMobile in direct-to-cell service.
Rocket Lab stock, by contrast, could ultimately benefit from tighter Falcon 9 availability, since its own reusable Neutron rocket recently completed a key engine test and could attract customers if Starship faces further delays. AST SpaceMobile stock is essentially flat over the past year, up just 0.4%, while Rocket Lab stock remains up 42% over that same span even after today’s decline.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Rocket Lab didn't make the cut. Grab the names FREE today.
What Tonight’s Launch Needs to Go Right Tonight’s flight will test whether SpaceX’s Super Heavy booster can complete a clean launch, stage separation, and a controlled return to an offshore landing point in the Gulf of Mexico. Starship itself needs to deploy 20 next-generation Starlink V3 satellites and complete its own controlled descent to a splashdown in the Indian Ocean, with several of the satellites carrying cameras to scan the heat shield during reentry.
Traders on Polymarket price an 81% chance of a successful launch tonight and a 72% chance of a controlled splashdown for Starship, odds that suggest confidence but hardly a sure thing. Raymond James analyst Brian Gesuale stated that “Starship becoming operational is the critical path to the SpaceX investment thesis,” a view that puts tonight’s test at the center of the bull case.
What to Watch Now For investors who don’t want to pick a single winner among SpaceX, Rocket Lab, and AST SpaceMobile stock, the Procure Space ETF (NASDAQ:UFO) offers diversified exposure to the space sector. The ETF is down just 1.5% today to $43.05, a milder decline that highlights the benefit of diversification, though the fund still carries concentration risk given its narrow focus on the space industry.
SpaceX stock appears to be the riskiest of the three names tonight, given its direct exposure to the test outcome, an approaching August 6 share lock-up expiration, and short interest that has reportedly grown to 32%. Rocket Lab stock and AST SpaceMobile stock face more indirect risk, since their declines today stem mainly from sentiment rather than any company-specific setback.
Given how much rides on a single rocket test, investors might choose to keep their position sizes modest across all three names until tonight’s outcome is clear. Investors can watch for whether Starship completes tonight’s flight and how SpaceX stock reacts heading into its August 4 earnings call and the August 6 lock-up expiration that follows.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Rocket Lab didn't make the cut. Grab the names FREE today.
Key Takeaways Cleveland-Cliffs posted a narrower Q2 loss as revenues rose 5.9% on higher steel pricing.Average steel selling price climbed 10.7%, lifting segment cash margin to $349 million.Q3 adjusted EBITDA is seen near $575 million, with Q4 expected to come in even higher. Cleveland-Cliffs Inc. (CLF - Free Report) reported second-quarter 2026 adjusted loss of 20 cents per share, narrower than the Zacks Consensus Estimate of a loss of 21 cents and the year-ago loss of 51 cents.
Revenues rose 5.9% year over year to $5.2 billion and surpassed the consensus estimate of $5.1 billion by 1.9%. Higher steel pricing supported the top line and margin improvement, although steel shipment volumes declined from the prior-year quarter.
Consolidated cost of goods sold declined to $5.1 billion from $5.15 billion a year earlier. Selling, general and administrative expenses rose to $154 million from $137 million, while restructuring and other charges decreased to $3 million from $86 million.
CLF's Operational HighlightsSteelmaking revenues increased 5.9% year over year to $5.05 million from $4.8 billion. The segment generated a cash margin of $349 million, up sharply from $138 million in the year-ago quarter, reflecting stronger selling prices and improved cost performance.
The average net selling price per net ton of steel products was $1,124, up 10.7% from $1,015 a year earlier. The metric was above the consensus estimate of $1,109.
External sales volumes for steel products totaled 4.025 million net tons, down 6.2% from 4.290 million net tons in the prior-year quarter. The figure missed the consensus estimate of 4.11 million net tons.
Financial Position of CLFCleveland-Cliffs ended the second quarter with cash and cash equivalents of $70 million, up from $57 million at the end of 2025. Long-term debt stood at $7.7 billion compared with $7.3 billion as of Dec. 31, 2025. The company had total liquidity of $3.1 billion as of June 30, 2026.
CLF's OutlookCleveland-Cliffs expects third-quarter 2026 adjusted EBITDA of approximately $575 million, more than double the second-quarter result. Management also expects fourth-quarter EBITDA to exceed its third-quarter guidance as average selling prices, shipment volumes and costs continue to move in a favorable direction.
CLF maintained its full-year 2026 steel shipment guidance of approximately 16.5-17 million net tons. The company continues to project capital expenditures of about $700 million, SG&A expenses of approximately $575 million and depreciation, depletion and amortization of roughly $1.1 billion.
Cash pension and other post-employment benefit payments and contributions remain projected at approximately $125 million. Management expects second-half earnings performance to be the company’s strongest since 2021 and believes it can reach its leverage target of less than 2.5 times debt to EBITDA by this time next year.
CLF’s Stock Price PerformanceCLF’s shares have lost 4.2% in the past year against the industry’s rise of 60.9%.
Image Source: Zacks Investment Research
CLF’s Zacks Rank & Other Key PicksCLF currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the basic materials space are Carpenter Technology Corporation (CRS - Free Report) , Kronos Worldwide, Inc. (KRO - Free Report) and Avient Corporation (AVNT - Free Report) .
Carpenter Technology is slated to report fourth-quarter fiscal 2026 results on July 30. The Zacks Consensus Estimate for earnings is pegged at $10.58 per share, indicating 41.44% year-over-year growth. CRS sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Kronos is scheduled to report second-quarter 2026 results on Aug. 5. The Zacks Consensus Estimate for KRO’s second-quarter loss per share is pegged at 33 cents, indicating 65.63% year-over-year growth. KRO flaunts a Zacks Rank #1 at present.
Avient is slated to report second-quarter 2026 results on Aug. 6. The consensus estimate for AVNT’s earnings per share is pegged at $3.08. AVNT presently carries a Zacks Rank #2.
